Advertisement
ARKG vs IXJ
Which ETF would AI Choose? ARK Genomic Revolution ETF (ARKG) vs. iShares Global Healthcare ETF (IXJ)
Key Takeaways
- ARKG is an actively managed thematic ETF targeting the genomics revolution, while IXJ is a passively managed fund tracking a broad global healthcare index.
- ARK Genomic Revolution ETF (ARKG) carries a higher expense ratio of 0.75% compared to 0.38% for iShares Global Healthcare ETF (IXJ), reflecting its active strategy versus passive indexing.
- ARKG concentrates on approximately 35 holdings focused on genomics, biotechnology, and related innovation, whereas IXJ holds over 100 securities across global pharmaceutical, biotech, and medical device companies.
- Top holdings in ARKG emphasize smaller, high-growth genomics firms such as 10x Genomics Inc (TXG) and Twist Bioscience Corp (TWST), while IXJ features large-cap leaders including Eli Lilly and Co (LLY) and Johnson & Johnson (JNJ).
- ARKG offers concentrated exposure to disruptive life sciences themes with elevated volatility potential, whereas IXJ provides diversified global healthcare sector access with broader stability.
- Both ETFs operate within the healthcare sector but differ significantly in risk profile, cost structure, and thematic versus broad-market positioning.
Introduction
Healthcare remains a pivotal sector for investors seeking growth from medical innovation and demographic shifts. ARK Genomic Revolution ETF (ARKG) and iShares Global Healthcare ETF (IXJ) provide distinct avenues into this space. ARKG pursues an active, thematic approach centered on genomics advancements, while IXJ delivers passive, diversified exposure to the global healthcare industry. These ETFs do not compete directly but serve as alternatives for investors balancing concentrated innovation bets against broad sector participation. The comparison highlights structural differences that influence risk, cost, and return drivers across market cycles.
ARK Genomic Revolution ETF (ARKG) Overview
ARK Genomic Revolution ETF (ARKG) is an actively managed exchange-traded fund launched in 2014 by ARK Investment Management. It seeks long-term capital growth by investing primarily in equity securities of companies involved in the genomics revolution, including gene editing, bioinformatics, and molecular medicine. The fund typically holds 34 to 40 securities and maintains high active share. Top holdings often include 10x Genomics Inc (TXG), Twist Bioscience Corp (TWST), Tempus AI Inc (TEM), CRISPR Therapeutics AG (CRSP), and Natera Inc (NTRA). Sector allocation concentrates heavily in healthcare and information technology. The expense ratio stands at 0.75%. ARKG employs discretionary rebalancing based on fundamental research rather than mechanical index rules, resulting in a focused, high-conviction portfolio.
iShares Global Healthcare ETF (IXJ) Overview
iShares Global Healthcare ETF (IXJ) is a passively managed fund launched in 2001 by BlackRock that tracks the S&P Global 1200 Health Care (Sector) Capped Index. It provides exposure to large- and mid-cap companies across the global healthcare sector, including pharmaceuticals, biotechnology, and medical equipment. The ETF holds approximately 109 securities. Top holdings typically feature Eli Lilly and Co (LLY), Johnson & Johnson (JNJ), AbbVie Inc (ABBV), UnitedHealth Group Inc (UNH), and Merck & Co Inc (MRK). Sector weights emphasize pharma, biotech, and life sciences alongside healthcare equipment and services. Geographic exposure spans the United States and international markets. The expense ratio is 0.38%. IXJ follows a rules-based methodology with periodic index rebalancing for broad, cost-efficient diversification.
Industry and Thematic Backdrop
The healthcare sector continues to benefit from long-term drivers including aging populations, advances in precision medicine, and sustained research and development spending. Genomics and biotechnology represent high-growth sub-themes within healthcare, supported by technological breakthroughs and regulatory pathways for novel therapies. Broader healthcare faces influences from drug pricing policies, patent expirations, and global supply chain considerations. Capital flows into life sciences innovation remain robust, while macroeconomic factors such as interest rate environments affect valuation multiples across both concentrated and diversified portfolios. Sector risks include clinical trial outcomes, competitive pressures, and evolving reimbursement frameworks.
Performance and Positioning Comparison
In recent market cycles, ARK Genomic Revolution ETF (ARKG) has exhibited greater volatility tied to the performance of its concentrated genomics holdings and sentiment around breakthrough technologies. iShares Global Healthcare ETF (IXJ) has delivered more measured returns aligned with established pharmaceutical and healthcare service companies. During periods of sector rotation favoring large-cap stability, IXJ has shown relative resilience. Conversely, ARKG has captured outsized moves when genomics catalysts emerge. The active strategy in ARKG allows adaptation to evolving scientific trends, while IXJ’s passive construction provides consistent exposure without manager discretion. Relative positioning favors ARKG for investors seeking thematic alpha and IXJ for those prioritizing cost efficiency and lower tracking error in broad healthcare exposure.
AI Screener
Tickeron’s AI Screener is an AI-powered stock and ETF discovery tool that helps traders and investors filter the market based on technical patterns, fundamentals, trends, volatility, and AI-driven signals. Users can scan thousands of stocks and ETFs using customizable filters such as industry, market capitalization, technical indicators, price patterns, and performance metrics. The screener helps identify trade ideas, trending stocks, breakout candidates, and market opportunities more efficiently than manual screening. AI Screener
Tickeron AI Verdict
Based on structural strength, cost efficiency, and diversification profile, Tickeron’s AI would likely assign a higher probability to iShares Global Healthcare ETF (IXJ) in the current environment. Its lower expense ratio, broader holdings, and passive replication of a global healthcare benchmark offer more consistent risk-adjusted characteristics compared with the higher-cost, concentrated thematic mandate of ARK Genomic Revolution ETF (ARKG). Investors prioritizing thematic genomics exposure may still find value in ARKG, but the AI assessment favors IXJ for balanced positioning.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is ARKG is a Hold and IXJ is a StrongBuy.
ARKG's MACD Histogram just turned positive
The Moving Average Convergence Divergence (MACD) for ARKG turned positive on October 28, 2026. Looking at past instances where ARKG's MACD turned positive, the stock continued to rise in 47 of 51 cases over the following month. The odds of a continued upward trend are 90%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The Momentum Indicator moved above the 0 level on October 27, 2026. You may want to consider a long position or call options on ARKG as a result. In 72 of 84 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 86%.
ARKG moved above its 50-day moving average on October 27, 2026 date and that indicates a change from a downward trend to an upward trend.
The 10-day moving average for ARKG crossed bullishly above the 50-day moving average on October 29, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In 22 of 23 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are 90%.
Following a +6.70% 3-day Advance, the price is estimated to grow further. Considering data from situations where ARKG advanced for three days, in 248 of 277 cases, the price rose further within the following month. The odds of a continued upward trend are 90%.
The Aroon Indicator entered an Uptrend today. In 202 of 220 cases where ARKG Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 90%.
Bearish Trend Analysis
The 10-day RSI Indicator for ARKG moved out of overbought territory on October 06, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 31 similar instances where the indicator moved out of overbought territory. In 28 of the 31 cases, the stock moved lower in the following days. This puts the odds of a move lower at 90%.
The Stochastic Oscillator has been in the overbought zone for 2 days. Expect a price pull-back in the near future.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where ARKG declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 90%.
ARKG broke above its upper Bollinger Band on October 27, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
IXJ in upward trend: 10-day moving average moved above 50-day moving average on October 19, 2026
The 10-day moving average for IXJ crossed bullishly above the 50-day moving average on October 19, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In 12 of 12 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are 90%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The Momentum Indicator moved above the 0 level on October 14, 2026. You may want to consider a long position or call options on IXJ as a result. In 72 of 92 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 78%.
The Moving Average Convergence Divergence (MACD) for IXJ just turned positive on October 12, 2026. Looking at past instances where IXJ's MACD turned positive, the stock continued to rise in 40 of 49 cases over the following month. The odds of a continued upward trend are 82%.
IXJ moved above its 50-day moving average on October 14, 2026 date and that indicates a change from a downward trend to an upward trend.
Following a +3.02% 3-day Advance, the price is estimated to grow further. Considering data from situations where IXJ advanced for three days, in 256 of 319 cases, the price rose further within the following month. The odds of a continued upward trend are 80%.
Bearish Trend Analysis
The RSI Indicator has been in the overbought zone for 1 day. Expect a price pull-back in the near future.
The Stochastic Oscillator demonstrated that the ticker has stayed in the overbought zone for 13 days. The longer the ticker stays in the overbought zone, the sooner a price pull-back is expected.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where IXJ declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 77%.
IXJ broke above its upper Bollinger Band on October 20, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
The Aroon Indicator for IXJ entered a downward trend on October 12, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
| ARKG | IXJ | |
|---|---|---|
| RSI ODDS (%) | 2 days ago 90% | 2 days ago 86% |
| Stochastic ODDS (%) | 2 days ago 90% | 2 days ago 79% |
| Momentum ODDS (%) | 2 days ago 86% | 2 days ago 78% |
| MACD ODDS (%) | 2 days ago 90% | 2 days ago 82% |
| TrendWeek ODDS (%) | 2 days ago 90% | 2 days ago 79% |
| TrendMonth ODDS (%) | 2 days ago 90% | 2 days ago 80% |
| Advances ODDS (%) | 3 days ago 90% | 2 days ago 80% |
| Declines ODDS (%) | 18 days ago 90% | 5 days ago 77% |
| BollingerBands ODDS (%) | 2 days ago 90% | 2 days ago 72% |
| Aroon ODDS (%) | 2 days ago 90% | 2 days ago 84% |
Advertisement
ARKG and
Correlation & Price change
A.I.dvisor indicates that over the last year, ARKG has been loosely correlated with DNA. These tickers have moved in lockstep 62% of the time. This A.I.-generated data suggests there is some statistical probability that if ARKG jumps, then DNA could also see price increases.
| Ticker / NAME | Correlation To ARKG | 1D Price Change % | ||
|---|---|---|---|---|
| ARKG | 100% | -6.73% | ||
| DNA - ARKG | 62% Loosely correlated | -12.01% | ||
| FATE - ARKG | 60% Loosely correlated | -4.15% | ||
| PHR - ARKG | 59% Loosely correlated | -0.72% | ||
| EDIT - ARKG | 59% Loosely correlated | -8.87% | ||
| BFLY - ARKG | 57% Loosely correlated | -14.91% | ||
More | ||||
IXJ and
Correlation & Price change
A.I.dvisor indicates that over the last year, IXJ has been closely correlated with LLY. These tickers have moved in lockstep 72% of the time. This A.I.-generated data suggests there is a high statistical probability that if IXJ jumps, then LLY could also see price increases.
| 1 Day | |||
|---|---|---|---|
| ETFs / NAME | Price $ | Chg $ | Chg % |
| AUSM | 24.97 | 0.02 | +0.06% |
| Allspring Ultra Short Municipal ETF (AUSM) | |||
| MDEV | 22.04 | N/A | N/A |
| First Trust Indxx Medical Devices ETF (MDEV) | |||
| CXSE | 31.24 | -0.32 | -1.01% |
| WisdomTree China ex-State-Owned Enterprises Fund (CXSE) | |||
| FVC | 43.26 | -0.49 | -1.13% |
| First Trust Dorsey Wright Dynamic Focus 5 ETF (FVC) | |||
| ROBO | 74.62 | -3.27 | -4.20% |
| ROBO Global Robotics & Automation Index ETF (ROBO) | |||